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Department of Pathology, Yonsei University College of Medicine, Seoul, South Korea
Cancer stem cell (CSC) markers have prognostic significance in various cancers, but
their clinical significance in papillary thyroid carcinoma (PTC) has not been demonstrated.
In this study, CSC markers expressed in PTC and their relationships with prognosis
were evaluated. We constructed tissue microarrays for 386 PTC cases, divided it
into 42 low risk cases and 344 intermediate risk cases according to the American
Thyroid Association 2009 Risk Stratification System. Immunohistochemical staining of
CSC markers (CD15, CD24, CD44, CD166, and ALDH1A1) was performed, and the
proportion of stained cells and immunostaining intensity were evaluated to determine
positive marker expression. The relationships between CSCmarker expression and other
clinicopathological parameters or survival were analyzed. CD15 expression was higher
in PTC with intermediate risk than in PTC with low risk (29.4 vs. 11.9%, p = 0.017).
According to a multivariate analysis, CD15, CD44, CD166, and ALDH1A1 positivity
were independently associated with a shorter progression-free survival (PFS) (odds
ratio [OR]: 1.929, 2.960, 7.485, and 3.736; p = 0.016, p = 0.026, p < 0.001, and
p = 0.006, respectively). Higher N and cancer stage were the only other clinical factors
associated with a shorter PFS (OR: 2.953 and 1.898, p = 0.011 and p = 0.034).
Overexpression of CSC markers in PTC was associated with shorter PFS during
follow-up. Immunohistochemical staining of CSCmarkers may provide useful information
for predicting patient outcomes.
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INTRODUCTION
Thyroid cancer is the most common type of endocrine-related cancer, affecting 3.2 million people
worldwide in 2015 (1). Among thyroid cancers, papillary thyroid cancer (PTC) accounts for
80–85% of cases. In general, the prognosis of PTC is favorable because of its low biological
aggressiveness (2–4). However, in cases of disease recurrence or metastasis owing to a poor
response or resistance to the standard treatment of thyroidectomy and radioactive iodine-131
therapy, patient death may occur and alternative treatment options should be sought. Therefore,
numerous efforts have been made to identify markers of aggressive cancer behaviors. While the
cause of aggressiveness in certain patients with PTC is unclear, several lines of evidence suggest
an association with a rare subpopulation of tumor cells with stem cell-like features, also known
as cancer stem cells (CSCs) (5, 6). CSCs have important roles in cancer development, growth,
recurrence, and metastasis owing to their potential to self-renew and differentiate into various cells
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lineages. These characteristics may result in the formation of
heterogenous tumor cell masses and the acquisition of resistance
to chemotherapy and radiotherapy (7–10).
The role of CSCs in malignancy was first demonstrated
in a leukemia model. While tumorigenesis is not provoked
in immunodeficient non-obese diabetic/severe combined
immunodeficiency mice upon transplantation of most tumor
cells, the transplantation of certain tumor cells induces
tumorigenesis (11). Subsequent studies have further evaluated
the role of CSCs in various solid and hematological malignancies.
For example, CSCs were found to be related to resistance to
therapy and poor prognosis in patients with esophageal and
breast cancer (12–15). In line with these findings, CSC marker
expression is correlated with poor prognosis in colorectal
carcinoma, suggesting that the expression of CSC markers is
associated with patient prognosis in various cancers (16, 17).
Several surrogate marker of CSCs have been previously
described. For example, CD24, CD44, and ALDHA1 have been
suggested to be CSC markers in breast cancer (13), and CD166
has been implicated in colon cancer (17). In a thyroid cancer
cell line, CD15, CD44, CD166, and ALDHA1 are markers of
thyroid epithelial cell stemness (18). Moreover, Xu et al. have
shown that SSEA-1 (CD15) immunoreactivity is associated with
an aggressive subtype of thyroid carcinoma (19). However,
the relationship between CSC marker expression and patient
prognosis in PTC remains unclear. Therefore, the objective of
this study was to investigate the expression of CSC markers in
PTC and evaluate its clinical significance.
MATERIALS AND METHODS
Cancer Stem Cell Marker Selection
To select candidate markers for CSCs, an in silico analysis
and literature review were performed and the most extensively
studied candidate markers were chosen (20, 21). CD44
expression was higher in thyroid cancer tissues than in
normal thyroid tissues according to the Gene Expression across
Normal and Tumor Tissue (GENT) web-accessible database
(http://medical-genome.kribb.re.kr/GENT). The web-accessible
database cBioPortal (http://www.cbioportal.org) was used to
evaluate CSC marker abnormalities in thyroid cancer tissues
(Supplementary Figure S1). As a result, CD15, CD24, CD44,
CD166, and ALDH1A1 were selected as markers of CSCs in
this study.
Patient Selection
A total of 386 patients pathologically diagnosed with PTC
at Severance Hospital who underwent the surgical removal
of cancer and for whom paraffin blocks were available were
recruited. Patients were divided into two groups, low risk
(n = 42) and intermediate risk (n = 344), according to the
American Thyroid Association 2009 Risk Stratification System
(22). All cases were retrospectively reviewed by a thyroid
pathologist (JSK), and histological evaluation was performed
after hematoxylin and eosin staining. Clinicopathological data
were obtained from medical records and included age at
diagnosis, sex, disease recurrence/metastasis, and all-cause
mortality. The T, N, and cancer stage (23), margin (expanding or
infiltrative), extent (confined to the thyroid parenchyma or with
extrathyroidal spread), and presence of BRAF V600E mutations
were also noted after reviewing the slides and surgical pathology
reports. This study was approved by the Institutional Review
Board of Severance Hospital and conducted in accordance with
the principles set forth in the Declaration of Helsinki. The
requirement to obtain informed consent was waived from the
Institutional Review Board of Severance Hospital because this
was a retrospective study.
Tissue Microarray
Representative areas were selected on hematoxylin and eosin-
stained slides, and a corresponding spot was marked on the
surface of the matching paraffin block. Tissue microarrays
(TMAs) were constructed from representative tissue columns for
the 386 PTC cases. Three-millimeter tissue cores were extracted
from the selected areas using a manual tissue arrayer and placed
into a 6× 5 recipient block. Two tissue cores were extracted from
each sample to minimize extraction bias. Each tissue core was
assigned a unique TMA location number, which was linked to
a database containing other clinicopathological data.
Immunohistochemistry
Antibodies used for immunohistochemistry are listed in
Supplementary Table S1. All immunohistochemical analyses
were performed with formalin-fixed, paraffin-embedded tissue
sections using an automatic immunohistochemistry staining
device (Benchmark XT; Ventana Medical System, Tucson,
AZ, USA). Briefly, 5-µm-thick formaldehyde-fixed, paraffin-
embedded tissue sections were transferred to adhesive slides and
dried at 62◦C for 30min. Standard heat epitope retrieval was
performed for 30min in ethylene diamine tetraacetic acid, pH
8.0, in an autostainer. The samples were then incubated with
primary antibodies. Afterwards, the sections were incubated with
biotinylated anti-mouse immunoglobulins, peroxidase-labeled
streptavidin (LSAB Kit, DakoCytomation, Agilent, Santa Clara,
CA, USA), and 3,3′-diaminobenzidine. Negative control samples
were processed without the primary antibody. Positive control
tissues were used per the manufacturer’s recommendation. Slides
were counterstained with Harris hematoxylin. Optimal primary
antibody incubation times and concentrations were determined
by serial dilutions using a tissue block fixed and embedded exactly
as performed for the samples.
Interpretation of Immunohistochemical
Staining
Immunohistochemical markers were assessed by light
microscopy. The stained slides were semi-quantitatively
evaluated as described previously (24). Staining was evaluated by
calculating the proportion of stained cells and immunostaining
intensity. The immunostaining intensity was defined as follows:
0, negative; 1, weak; 2, moderate; and 3, strong. The scores for
the proportion of stained cells and immunostaining intensity
were multiplied, and staining was defined as positive when the
final score was >10. BRAF V600E mutation status was evaluated
using immunohistochemical staining, and was considered
positive when >20% of tumor cells were positive (25).
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TABLE 1 | Clinicopathological features of patients with papillary thyroid carcinoma
according to the American Thyroid Association 2009 Risk Stratification System.
Total
N = 386 (%)
ATA low risk
group
n = 42 (%)
ATA
intermediate
risk group
n = 344 (%)
p-value
Age (years) 0.370
<45 168 (43.5) 21 (50.0) 147 (42.7)
≥45 218 (56.5) 21 (50.0) 197 (57.3)
Sex 0.634
Male 81 (21.0) 10 (23.8) 71 (20.6)
Female 305 (79.0) 32 (76.2) 273 (79.4)
T stage 0.260
T1 279 (72.3) 33 (78.6) 246 (71.5)
T2 100 (25.9) 9 (21.4) 91 (26.5)
T3 7 (1.8) 0 (0.0) 7 (2.0)
N stage <0.001
N0 144 (37.3) 28 (66.7) 116 (33.7)
N1 242 (62.7) 14 (33.3) 228 (66.3)
Cancer stage 0.006
I 268 (69.4) 37 (88.1) 231 (67.2)
II 118 (30.6) 5 (11.9) 113 (32.8)
Expanding margin <0.001
No 328 (85.0) 19 (45.2) 309 (89.8)
Yes 58 (15.0) 23 (54.8) 35 (10.2)
Tumor extension <0.001
Intrathyroidal 110 (28.5) 42 (100.0) 68 (19.8)
Extrathyroidal 276 (71.5) 0 (0.0) 276 (80.2)
BRAF V600E mutation (n = 320)* <0.001
No 95 (29.7) 30 (100.0) 65 (22.4)
Yes 225 (70.3) 0 (0.0) 225 (77.6)
Recurrence/metastasis 0.792
No 327 (84.7) 35 (83.3) 292 (84.9)
Yes 59 (15.3) 7 (16.7) 52 (15.1)
Mortality 0.246
No 367 (95.1) 42 (100.0) 325 (94.5)
Yes 19 (4.9) 0 (0.0) 19 (5.5)
*Cases that were not tested for the BRAF V600E mutation were excluded. ATA, American
thyroid association. Bold values indicate statistically significant (p < 0.05).
Statistical Analysis
All data are presented as frequencies and percentages. Data
were compared using the Chi-squared test or Fisher’s exact test,
as appropriate. Associations between the proportion of CSC
marker-stained cells and BRAF V600E mutation status were
analyzed using Spearman’s rho. Univariate and multivariate Cox
proportional hazard analyses were used to evaluate prognostic
factors for progression-free survival (PFS) and overall survival
(OS). For all statistical analyses, a two-tailed p-value of< 0.05 was
considered statistically significant. Data analyses were performed
using IBM SPSS Statistics for Windows, Version 21.0 (Released
2012; IBM Corp., Armonk, NY, USA).
RESULTS
Baseline Characteristics of Patients
The clinicopathological features of patients included in this
study are presented in Table 1. Among the patients, 305 (79.0%)
were female, and the mean age was 47.0 years (range: 20–82
TABLE 2 | Expression of cancer stem cell markers according to the American
Thyroid Association 2009 Risk Stratification System.
Total
N = 386 (%)
ATA low risk
group
n = 42 (%)
ATA intermediate
risk group
n = 344 (%)
p-value
CD15 0.017
Negative 280 (72.5) 37 (88.1) 243 (70.6)
Positive 106 (27.5) 5 (11.9) 101 (29.4)
CD24 0.999
Negative 384 (99.5) 42 (100.0) 342 (94.4)
Positive 2 (0.5) 0 (0.0) 2 (0.6)
CD44 0.052
Negative 76 (19.7) 13 (31.0) 63 (18.3)
Positive 310 (80.3) 29 (69.0) 281 (81.7)
CD166 0.347
Negative 339 (87.8) 35 (83.3) 304 (88.4)
Positive 47 (12.2) 7 (16.7) 40 (11.6)
ALDH1A1 0.212
Negative 378 (97.9) 40 (95.2) 338 (98.3)
Positive 8 (2.1) 2 (4.8) 6 (1.7)
ATA, American thyroid association. Bold value indicates statistically significant (p < 0.05).
years). The N and cancer stages were higher in patients in the
intermediate risk group than in those in the low risk group.
Moreover, infiltrative margins, extrathyroidal extension, and
BRAF V600E mutation were more frequently observed in PTC
with intermediate risk than in the low risk group. No significant
differences were found with respect to age, gender, T stage,
recurrence/metastasis, and mortality between the two groups.
Expression of CSC Markers in the Low and
Intermediate Risk Groups
Among the CSC markers, CD44 positivity was most frequent,
followed by CD166 positivity and CD15 positivity. The
expression of CD15 was significantly higher in the intermediate
risk group than in the low risk group (29.4 vs. 11.9%, p = 0.017;
Table 2). CD24 positivity was found in only 2 (0.5%) cases, and
there was no statistical difference in the expression of CD24
between the two groups. A heat map of CSC marker expression
and representative images of immunohistochemical staining of
CSC markers in PTC with low risk and intermediate risk are
shown in Figures 1, 2.
Correlations Between CSC Marker
Expression and Clinicopathological
Factors in PTC
We investigated the correlations between the expression of
CSC markers and clinicopathological factors in PTC. CD15
positivity was associated with older age (≥45 years; p = 0.036),
infiltrative margins (p = 0.002), BRAF V600E mutation
(p < 0.001), and recurrence/metastasis (p = 0.014; Figure 3).
Similarly, CD44 positivity was associated with a higher N stage
(p = 0.022), infiltrative margins (p < 0.001), extrathyroidal
involvement (p = 0.038), and recurrence/metastasis (p = 0.019).
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FIGURE 1 | Heat map of cancer stem cell markers expressed in papillary thyroid carcinoma with ATA low risk and ATA intermediate risk.
FIGURE 2 | Expression of cancer stem cell markers in papillary thyroid carcinoma with ATA low risk and ATA intermediate risk. The expression of CD15 was higher in
PTCs with ATA intermediate risk ×100.
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FIGURE 3 | Expression of cancer stem cell marker CD15 and its association with clinicopathologic factors.
FIGURE 4 | Expression of cancer stem cell markers CD44, CD166, ALDH1A1, and clinicopathological factors. LN, lymph node.
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TABLE 3 | Correlations between cancer stem cell marker expression and BRAF
V600E mutation status.
Parameters Total (n = 320) PTC with lymph node
metastasis (n = 188)
Correlation
coefficient
p-value Correlation
coefficient
p-value
CD15 0.393 <0.001 0.367 <0.001
CD24 0.124 0.026 0.111 0.130
CD44 −0.050 0.369 −0.050 0.497
CD166 −0.045 0.427 −0.095 0.194
ALDH1A1 −0.024 0.668 −0.052 0.481
PTC, papillary thyroid carcinoma. Bold values indicate statistically significant (p < 0.05).
CD166 positivity was associated with BRAF V600E mutation
and recurrence/metastasis (p = 0.040 and p < 0.001,
respectively), and ALDH1A1 positivity was associated with
recurrence/metastasis (p < 0.001; Figure 4).
Correlations Between CSC Markers and
BRAF V600E Mutation Status
The BRAF V600E mutation status was evaluated by
immunohistochemistry in 320 cases of PTC. In total, 225
of the cases (70.3%) exhibited the BRAF V600E mutation. The
proportions of CD15- and CD24-stained cells were correlated
with the BRAF V600E mutation status (r = 0.393, p < 0.001
and r = 0.124, p = 0.026; Table 3). An association between
CD15-stained cells and BRAF V600E mutation status was also
observed in PTC cases with lymph node metastasis (r = 0.367,
p < 0.001). However, no significant correlations were observed
between the frequencies of the remaining CSC markers and the
BRAF V600E mutation status.
CSC Marker Expression Is Associated With
Disease Recurrence or Metastasis in PTC
We investigated the impact of clinical parameters and CSC
marker expression on the clinical outcomes of patients with PTC
using a Cox proportional hazard analysis. The mean follow-
up period was 79.1 months, with 59 patients (15.3%) suffering
recurrence or metastasis and 19 patients (4.9%) dying during the
follow-up period. According to a univariate analysis, higher N
and cancer stages, extrathyroidal involvement, and CD15, CD44,
CD166, and ALDH1A1 positivity were related to a shorter PFS.
A multivariate analysis revealed that a higher N stage [odds
ratio (OR): 2.953, 95% confidence interval (CI): 1.286–6.783,
p = 0.011], higher cancer stage (OR: 1.898, 95% CI: 1.050–
3.430, p = 0.034), CD15 positivity (OR: 1.929, 95% CI: 1.132–
3.288, p = 0.016), CD44 positivity (OR: 2.960, 95% CI: 1.137–
7.704, p = 0.026), CD166 positivity (OR: 7.485, 95% CI: 4.333–
12.930, p < 0.001), and ALDH1A1 positivity (OR: 3.736, 95%
CI: 1.467–9.515, p = 0.006) were independently associated with
a shorter PFS. However, only a higher cancer stage (OR: 6.839,
95% CI: 2.462–19.000, p < 0.010) was associated with a shorter
OS according to univariate and multivariate analyses (Table 4). TA
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DISCUSSION
In this study, we evaluated the expression of CSC markers in
PTC and their correlations with clinicopathological parameters
and prognosis. We found that in PTC with intermediate risk,
the expression of the CSC marker CD15 was significantly
elevated. Furthermore, the CSC markers CD15, CD44, CD166,
and ALDH1A1 were associated with an aggressive phenotype
and were each independently associated with a shorter PFS.
The findings of our study are consistent with those of previous
studies demonstrating that CSC marker expression is associated
with aggressive biological features in various cancers (26–28).
Collectively, our findings suggest that CSC markers are potential
biological markers for PTC.
In a previous study, CD15 positivity was associated with poor
survival in anaplastic thyroid cancer (19). Furthermore, Han et al.
have demonstrated that CD24 and CD44 are associated with
aggressive clinicopathological features in PTC (29). Together,
these findings suggest that the expression of CSC markers may
be associated with prognosis. In this study, among the five
CSC markers analyzed, we found that CD15, CD44, CD166,
and ALDH1A1 expression were independently associated with
a shorter PFS. These results provide the first evidence that the
expression of CSC markers is associated with patient prognosis
in PTC. However, in a Cox proportional hazard analysis,
only a higher cancer stage, but not CSC marker expression,
was related to patient OS. This may be explained by the
nature of PTC, which is relatively indolent compared to other
malignancies (3, 4).
Several cellular pathways may mediate the link between CSCs
and the pathogenesis of PTC, namely the Notch, Hedgehog
(Hh), and Wnt/β-catenin pathways. The Notch pathway is
known to facilitate the self-renewal of CSCs in various cancers
and is involved in the interaction between the tumor stroma
and the endothelium of the CSC microenvironment (30, 31).
The Hh pathway is reportedly related to the maintenance of
CSCs (32), and the activation of this pathway in cancers is
associated with the development of resistance to chemotherapy
or radiotherapy (33). The Wnt/β-catenin pathway has also been
suggested to play an important role in CSC maintenance (34).
Interestingly, a previous study has demonstrated that in PTC,
the activation of molecules related to the β-catenin pathway
in isolated CSCs promoted cancer migration and metastasis
(34). Furthermore, loss-of-function mutations in adenomatosus
polyposis coli is associated with CSC activation via β-catenin
activation and enhancement of KRAS mutation in colorectal
cancer tumorigenesis (35). Because RAS mutation has also been
identified in PTC as well as BRAF mutation, these findings
altogether suggest an association between CSC and PTC (36).
In a correlation analysis, the expression of the CSC
markers CD15 and CD24 was significantly correlated with
the BRAF V600E mutation status. In PTC, the BRAF V600E
mutation is reportedly associated with extrathyroidal extension,
multifocality, advanced cancer stage, lymph node metastasis,
and recurrence (37). A possible explanation for the association
between the BRAF V600E mutation status and the expression
of CSC markers may involve c-MYC and HIF-1α, which are
downstream molecules of the mitogen-activated protein kinase
pathway. In human ovarian cancer cells, HIF-1α promotes
CSC-like properties by upregulating SIRT1 expression (38). In
addition, c-MYC overexpression leads to a significant increase
in CSCs in breast cancer cell lines (39). Interestingly, Han et al.
(29) recently showed that the BRAF V600Emutation is associated
with CD44 expression in PTC with lymph node metastasis.
However, in our study, a significant relationship between CD44
expression and the BRAF V600E mutation status was not
observed. This difference among studies can likely be attributed
to the difference in antibodies used for immunohistochemistry
and differences in patient clinical characteristics; further studies
are required to evaluate the association between the BRAF V600E
mutation and the expression of CSC markers.
Our study has several important clinical implications. First,
our findings suggest that CSC markers may have prognostic
value in PTC. Lymph node involvement, infiltrative margins, and
lymphovascular invasion are pathological factors traditionally
associated with disease recurrence or metastasis in PTC (40).
However, other biological markers reflecting disease recurrence
or metastasis are largely unclear. Although a majority of PTCs
are indolent in nature, the prognosis for PTC with recurrence
or metastasis could be unfavorable (41, 42). Accordingly, it is
necessary to identify markers for the identification of patients
with high risk of disease recurrence or metastasis. Currently, the
American Thyroid Association 2009 Risk Stratification System is
the most widely accepted recommendation regarding the initial
management of thyroid cancer, which includes cancer screening,
staging and risk assessment, and treatment (22). Of note, in the
present study, the expression of CD15 was significantly higher
in the ATA intermediate risk group than in the low risk group.
Moreover, CD15, CD44, CD166, and ALDH1A1 positivity were
each independently associated with a shorter PFS, independently
of higher N and cancer stage as well as other clinicopathological
factors. These findings suggest that CSC markers are ancillary
biological markers for evaluating patient prognosis in PTC.
Second, CSCs may be potential therapeutic targets for the
treatment of PTC. The role of CSCs in PTC tumorigenesis
remains uncertain. However, owing to their important functions
in tumor initiation and the development of treatment resistance,
targeting CSCs may be useful for preventing cancer recurrence
or metastasis (43, 44). Currently, the first-line therapy for PTC
mainly consists of thyroidectomy and radioactive iodine-131
therapy, which targets mature tumor cells; however, in iodine
treatment-refractory cases with disease recurrence or metastasis,
chemotherapy using tyrosine kinase inhibitors is recommended
(45). Nevertheless, considering the aggressive nature and the
difficulty in controlling PTC with recurrence or metastasis (41),
there is a need for additional therapeutic options. Targeting CSCs
in PTC is a promising strategy for preventing tumor growth,
invasion, and metastasis; however, this should be confirmed in
clinical trials.
There are several limitations of this study. First, we used
immunohistochemistry to evaluate the expression of CSC
markers; the quantification of results is therefore difficult and
there is the potential for inter-observer bias. Second, as a TMA
was used rather than whole sections for histological examination,
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samples may have been influenced by extraction bias during
TMA construction. Third, we were not able to evaluate molecular
changes or the mechanisms underlying CSC marker expression
in thyroid cancer tissues, as we focused on expression at
the protein level. Fourth, the study was retrospective and
selection bias is possible. Further experiments are therefore
necessary to elucidate the expression of CSC markers at the
gene level and their contributions to the pathogenesis of
the disease.
In conclusion, we found that the expression of the CSCmarker
CD15 was higher in the ATA intermediate risk group than in
the low risk group and that the expression of CSC markers is
associated with more aggressive tumor characteristics and poor
prognosis, thus providing a rationale to evaluate CSC markers
in PTC.
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